Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YAPPETIZER study of neoadjuvant chemotherapy with or without zoledronic acid and atorvastatin in triple-negative breast cancer
2016-005112-17Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zoledronic acid and atorvastatin in triple-negative breast cancer (TNBC) (2 arms), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoints: Relative reduction of YAP IHC expression and Relative reduction of TAZ IHC expression. Started Jun 2021; status: completed.
02
Drugs
zoledronic acidatorvastatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2016-005112-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005112-17.